A Phase I dose-escalation study of the BRAF inhibitor vemurafenib in combination with the MTOR inhibitor everolimus in subjects with advanced cancer
作者： Javier Munoz
DOI:
关键词:
摘要: Vemurafenib has been approved in the United States for treatment of relapsed or refractory BRAF mutation positive malignant melanoma and is being investigated various other malignancies. The RAS/RAF/MEK/ERK (MAPK) pathway critical to cell proliferation many human cancers. mTOR inhibitors are well known exert profound anticancer effects across malignancies through inhibition PTEN/PI3K/AKT/mTOR (mTOR) pathway. We hypothesize that toxicity profile combination vemurafenib everolimus will be tolerated. primary objective find maximum tolerated dose (MTD) following a standard 3 + design. most common diagnosis was 5 out 10 patients
tmc.edu参考文章(135)
John A. Curtin, Jane Fridlyand, Toshiro Kageshita, Hetal N. Patel, Klaus J. Busam, Heinz Kutzner, Kwang-Hyun Cho, Setsuya Aiba, Eva-Bettina Bröcker, Philip E. LeBoit, Dan Pinkel, Boris C. Bastian, Distinct Sets of Genetic Alterations in Melanoma The New England Journal of Medicine. ,vol. 353, pp. 2135- 2147 ,(2005) , 10.1056/NEJMOA050092
Margaret K. Callahan, Raajit Rampal, James J. Harding, Virginia M. Klimek, Young Rock Chung, Taha Merghoub, Jedd D. Wolchok, David B. Solit, Neal Rosen, Omar Abdel-Wahab, Ross L. Levine, Paul B. Chapman, Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment The New England Journal of Medicine. ,vol. 367, pp. 2316- 2321 ,(2012) , 10.1056/NEJMOA1208958
Gregory J. Riely, Mark G. Kris, Daniel Rosenbaum, Jenifer Marks, Allan Li, Dhananjay A. Chitale, Khedoudja Nafa, Elyn R. Riedel, Meier Hsu, William Pao, Vincent A. Miller, Marc Ladanyi, Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clinical Cancer Research. ,vol. 14, pp. 5731- 5734 ,(2008) , 10.1158/1078-0432.CCR-08-0646
Cameron J. M. Wright, Paul L. McCormack, Trametinib: First Global Approval Drugs. ,vol. 73, pp. 1245- 1254 ,(2013) , 10.1007/S40265-013-0096-1
Eric R. Fearon, Bert Vogelstein, A genetic model for colorectal tumorigenesis Cell. ,vol. 61, pp. 759- 767 ,(1990) , 10.1016/0092-8674(90)90186-I
Rachael Anforth, Pablo Fernandez-Peñas, Georgina V Long, Cutaneous toxicities of RAF inhibitors Lancet Oncology. ,vol. 14, ,(2013) , 10.1016/S1470-2045(12)70413-8
Jeffrey A Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R Guimaraes, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A Perera, Youngchul Song, Lucian R Chirieac, Ramneet Kaur, Angela Lightbown, Jessica Simendinger, Timothy Li, Robert F Padera, Carlos García-Echeverría, Ralph Weissleder, Umar Mahmood, Lewis C Cantley, Kwok-Kin Wong, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nature Medicine. ,vol. 14, pp. 1351- 1356 ,(2008) , 10.1038/NM.1890
Javier Munoz, Filip Janku, Philip R. Cohen, Razelle Kurzrock, Erdheim-Chester Disease: Characteristics and Management Mayo Clinic Proceedings. ,vol. 89, pp. 985- 996 ,(2014) , 10.1016/J.MAYOCP.2014.01.023
Carlo Spirli, Carola M. Morell, Luigi Locatelli, Stefano Okolicsanyi, Cecilia Ferrero, Amy K. Kim, Luca Fabris, Romina Fiorotto, Mario Strazzabosco, Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with Sorafenib Hepatology. ,vol. 56, pp. 2363- 2374 ,(2012) , 10.1002/HEP.25872
Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag, Kevan M. Shokat, Neal Rosen, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature. ,vol. 464, pp. 427- 430 ,(2010) , 10.1038/NATURE08902